Editas Medicine Stock Revenue
| EDIT Stock | USD 2.24 0.04 1.82% |
Editas Medicine fundamentals help investors to digest information that contributes to Editas Medicine's financial success or failures. It also enables traders to predict the movement of Editas Stock. The fundamental analysis module provides a way to measure Editas Medicine's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Editas Medicine stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 78.1 M | 82 M |
Editas | Revenue |
Editas Medicine Company Revenue Analysis
Editas Medicine's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Editas Medicine Revenue | 78.12 M |
Most of Editas Medicine's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Editas Medicine is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Editas
Projected quarterly revenue analysis of Editas Medicine provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Editas Medicine match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Editas Medicine's stock price.
Editas Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Editas Medicine is extremely important. It helps to project a fair market value of Editas Stock properly, considering its historical fundamentals such as Revenue. Since Editas Medicine's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Editas Medicine's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Editas Medicine's interrelated accounts and indicators.
| 0.47 | 0.57 | -0.68 | 0.55 | 0.69 | ||
| 0.47 | 0.9 | -0.8 | 0.98 | 0.86 | ||
| 0.57 | 0.9 | -0.76 | 0.89 | 0.82 | ||
| -0.68 | -0.8 | -0.76 | -0.81 | -0.97 | ||
| 0.55 | 0.98 | 0.89 | -0.81 | 0.88 | ||
| 0.69 | 0.86 | 0.82 | -0.97 | 0.88 |
Click cells to compare fundamentals
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Editas Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Editas Medicine reported 78.12 M of revenue. This is 98.98% lower than that of the Biotechnology sector and 89.48% lower than that of the Health Care industry. The revenue for all United States stocks is 99.17% higher than that of the company.
Editas Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Editas Medicine's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Editas Medicine could also be used in its relative valuation, which is a method of valuing Editas Medicine by comparing valuation metrics of similar companies.Editas Medicine is currently under evaluation in revenue category among its peers.
Editas Medicine Current Valuation Drivers
We derive many important indicators used in calculating different scores of Editas Medicine from analyzing Editas Medicine's financial statements. These drivers represent accounts that assess Editas Medicine's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Editas Medicine's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.5B | 4.1B | 1.8B | 609.1M | 769.5M | 1.0B | |
| Enterprise Value | 1.3B | 4.0B | 1.6B | 511.5M | 682.4M | 921.9M |
Editas Medicine ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Editas Medicine's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Editas Medicine's managers, analysts, and investors.Environmental | Governance | Social |
Editas Medicine Institutional Holders
Institutional Holdings refers to the ownership stake in Editas Medicine that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Editas Medicine's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Editas Medicine's value.| Shares | Goldman Sachs Group Inc | 2024-06-30 | 1.2 M | Woodline Partners Lp | 2024-06-30 | 970.5 K | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 897.5 K | Two Sigma Advisers, Llc | 2024-06-30 | 856.5 K | Jpmorgan Chase & Co | 2024-06-30 | 799.2 K | Northern Trust Corp | 2024-09-30 | 703.8 K | Squarepoint Ops Llc | 2024-06-30 | 694.2 K | Charles Schwab Investment Management Inc | 2024-09-30 | 617.3 K | Raymond James & Associates | 2024-09-30 | 561.4 K | Blackrock Inc | 2024-06-30 | 7.8 M | Vanguard Group Inc | 2024-09-30 | 6.7 M |
Editas Fundamentals
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | (44.99 M) | ||||
| Shares Outstanding | 82.55 M | ||||
| Shares Owned By Insiders | 0.32 % | ||||
| Shares Owned By Institutions | 70.13 % | ||||
| Number Of Shares Shorted | 15.91 M | ||||
| Price To Earning | (7.02) X | ||||
| Price To Book | 1.03 X | ||||
| Price To Sales | 2.94 X | ||||
| Revenue | 78.12 M | ||||
| Gross Profit | (155.25 M) | ||||
| EBITDA | (163.12 M) | ||||
| Net Income | (153.22 M) | ||||
| Cash And Equivalents | 452.56 M | ||||
| Cash Per Share | 6.59 X | ||||
| Total Debt | 36.54 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 12.67 X | ||||
| Book Value Per Share | 2.13 X | ||||
| Cash Flow From Operations | (132.18 M) | ||||
| Short Ratio | 7.61 X | ||||
| Earnings Per Share | (2.54) X | ||||
| Target Price | 8.21 | ||||
| Number Of Employees | 265 | ||||
| Beta | 2.01 | ||||
| Market Capitalization | 181.61 M | ||||
| Total Asset | 499.15 M | ||||
| Retained Earnings | (1.23 B) | ||||
| Working Capital | 277.61 M | ||||
| Current Asset | 144.99 M | ||||
| Current Liabilities | 6.92 M | ||||
| Net Asset | 499.15 M |
About Editas Medicine Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Editas Medicine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Editas Medicine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Editas Medicine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.